Micro RNAs and chronic, low-grade inflammation
Micro RNA 与慢性、低度炎症
基本信息
- 批准号:9065475
- 负责人:
- 金额:$ 33.53万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-05-15 至 2020-04-30
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdoptive TransferAgeAgingAging-Related ProcessAnimalsAnti-Inflammatory AgentsAnti-inflammatoryAreaAutoantibodiesAutoimmunityB-LymphocytesBiological AssayChronicClinicClinicalComplexDataDevelopmentDiagnosticDiseaseExcisionGene ExpressionGene TargetingGeneticHealthHelper-Inducer T-LymphocyteHumanImmuneIndividualInflammationInflammatoryInflammatory ResponseInterleukin-6InvestigationKnowledgeLifeLongevityMalignant NeoplasmsMessenger RNAMetabolismMethodsMicroRNAsModelingMolecularMusNF-kappa BOlder PopulationPathway interactionsPatientsPhenotypePlayProcessProductionPropertyRegulationResearchRoleSerumStructure of germinal center of lymph nodeSymptomsT cell responseT-LymphocyteTestingTherapeuticTimeTissuesTranscription Factor AP-1TranslatingWorkage relatedbasebody systemcell growth regulationdisease phenotypegenetic approachhuman diseaseindividual patientinflammatory markerinsightmiddle agemortalitymouse modelnew therapeutic targetnovelnovel markeroverexpressionpreventresearch studystemtargeted treatmenttherapeutic targettranscription factor
项目摘要
DESCRIPTION (provided by applicant): Chronic, low-grade inflammation is a contributing factor to most age-related human diseases. However, the molecular mechanisms that sustain chronic inflammatory responses during aging remain poorly understood making it difficult to treat this deleterious condition. Over the past few years, studies have indicated that mammalian noncoding microRNAs (miRNAs) regulate a variety of acute inflammatory responses in young mice. We hypothesize that miRNAs also play critical roles in gauging inflammation during the aging process. Consistent with this, removal of miR-146a has recently been shown to cause an age-dependent inflammatory disease that recapitulates many aspects of chronic inflammation in patients, including progression to life-shortening disorders like cancer. We have used the miR-146a-/- model to identify and study other miRNAs that promote age-related inflammation, and have determined that miR-155 is necessary for disease to emerge in the miR-146a-/- mouse model. We have also found that miR-155 is required for spontaneous accumulation of T follicular helper cells, autoantibody production and the subsequent tissue inflammation that emerges in middle-aged miR-146a-/- mice. Further, we also have preliminary data indicating a T cell-intrinsic role for miR-155 as it promotes chronic inflammation in miR-146a-/- mice. We will carry out a research plan to determine which downstream phenotypes in miR-146a-/- are dependent on miR-155 function in T cells, and also determine the specific contribution by Tfh cells. The molecular mechanism by which miR-155 instructs Tfh cell development in miR-146a-/- mice will also be investigated. Furthermore, we will extend our studies into the clinic and determine if miR-155 and Tfh cell levels correlate with other markers of chronic, low-grade inflammation in "healthy" middle aged patients. Taken together, our research plan will provide valuable insight into the mechanisms underlying chronic inflammation, and determine whether miR-155 and Tfh cells are promising therapeutic targets with the potential to reduce chronic, low-grade inflammation and the myriad of diseases that stem from this pathological condition.
描述(由申请人提供):慢性低度炎症是大多数与年龄相关的人类疾病的一个促成因素。然而,在衰老期间维持慢性炎症反应的分子机制仍然知之甚少,使得难以治疗这种有害的病症。在过去的几年里,研究表明,哺乳动物非编码microRNAs(miRNAs)调节各种急性炎症反应在年轻的小鼠。我们推测,miRNAs在衡量衰老过程中的炎症方面也起着关键作用。与此相一致,最近已显示去除miR-146a会导致年龄依赖性炎症性疾病,该疾病重演了患者慢性炎症的许多方面,包括进展为缩短寿命的疾病,如癌症。我们使用miR-146a-/-模型来鉴定和研究促进年龄相关炎症的其他miRNA,并确定miR-155是miR-146a-/-小鼠模型中出现疾病所必需的。我们还发现,miR-155是中年miR-146a-/-小鼠中T滤泡辅助细胞自发积累、自身抗体产生和随后出现的组织炎症所必需的。此外,我们也有初步数据表明miR-155的T细胞内在作用,因为它促进miR-146a-/-小鼠的慢性炎症。我们将开展一项研究计划,以确定miR-146a-/-中哪些下游表型依赖于T细胞中miR-155的功能,并确定Tfh细胞的具体贡献。还将研究miR-155指导miR-146a-/-小鼠中Tfh细胞发育的分子机制。此外,我们将把我们的研究扩展到临床,并确定miR-155和Tfh细胞水平是否与“健康”中年患者的慢性低度炎症的其他标志物相关。总之,我们的研究计划将为慢性炎症的潜在机制提供有价值的见解,并确定miR-155和Tfh细胞是否是有希望的治疗靶点,有可能减少慢性,低度炎症和源于这种病理状态的无数疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ryan M O'Connell其他文献
MiR-23b is a safeguard against autoimmunity
miR-23b 是针对自身免疫的一种保护措施
- DOI:
10.1038/nm.2849 - 发表时间:
2012-07-06 - 期刊:
- 影响因子:50.000
- 作者:
Ruozhen Hu;Ryan M O'Connell - 通讯作者:
Ryan M O'Connell
MicroRNAs: new regulators of immune cell development and function
微小 RNA:免疫细胞发育和功能的新调节因子
- DOI:
10.1038/ni.f.209 - 发表时间:
2008-07-21 - 期刊:
- 影响因子:27.600
- 作者:
David Baltimore;Mark P Boldin;Ryan M O'Connell;Dinesh S Rao;Konstantin D Taganov - 通讯作者:
Konstantin D Taganov
Ryan M O'Connell的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ryan M O'Connell', 18)}}的其他基金
Intermountain Doctoral Education to Advance Students (IDEAS) in Neuroscience
神经科学高级学生山间博士教育(IDEAS)
- 批准号:
10611717 - 财政年份:2023
- 资助金额:
$ 33.53万 - 项目类别:
Metabolic regulation of macrophage microRNAs during colitis
结肠炎期间巨噬细胞 microRNA 的代谢调节
- 批准号:
10285819 - 财政年份:2021
- 资助金额:
$ 33.53万 - 项目类别:
Metabolic regulation of macrophage microRNAs during colitis
结肠炎期间巨噬细胞 microRNA 的代谢调节
- 批准号:
10456153 - 财政年份:2021
- 资助金额:
$ 33.53万 - 项目类别:
The Neuroimmunology Training Program at the University of Utah
犹他大学神经免疫学培训项目
- 批准号:
10621297 - 财政年份:2020
- 资助金额:
$ 33.53万 - 项目类别:
The Neuroimmunology Training Program at the University of Utah
犹他大学神经免疫学培训项目
- 批准号:
10426218 - 财政年份:2020
- 资助金额:
$ 33.53万 - 项目类别:
The Neuroimmunology Training Program at the University of Utah
犹他大学神经免疫学培训项目
- 批准号:
10210311 - 财政年份:2020
- 资助金额:
$ 33.53万 - 项目类别:
Investigating the transfer of miRNAs by exosomes during inflammation
研究炎症过程中外泌体的 miRNA 转移
- 批准号:
9310060 - 财政年份:2017
- 资助金额:
$ 33.53万 - 项目类别:
Investigating the transfer of miRNAs by exosomes during inflammation
研究炎症过程中外泌体的 miRNA 转移
- 批准号:
9891940 - 财政年份:2017
- 资助金额:
$ 33.53万 - 项目类别:
Utilizing TALEN technology to regulate human microRNA's
利用TALEN技术调控人类microRNA
- 批准号:
8568549 - 财政年份:2013
- 资助金额:
$ 33.53万 - 项目类别:
Investigate the Role of Micro-RNA 155 in Myeloid Development during Inflammation
研究 Micro-RNA 155 在炎症过程中骨髓发育中的作用
- 批准号:
8316418 - 财政年份:2011
- 资助金额:
$ 33.53万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 33.53万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 33.53万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 33.53万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 33.53万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 33.53万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 33.53万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 33.53万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 33.53万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 33.53万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 33.53万 - 项目类别:














{{item.name}}会员




